Notizie Newsletter
Screening Rates Rose Among People Aged 45–49 After Release of Updated Colorectal Cancer Guidelines
January 2, 2020 - Colorectal cancer screening rates more than doubled among people aged 45 to 49 in the months after the release of updated American Cancer Society guidelines in 2018 recommending screening in that age group, according to a new study. According to the findings ...Leggi tutto
FDA finalizes enforcement policy on unauthorized flavored cartridge-based e-cigarettes that appeal to children, including fruit and mint
January 2, 2020 - Amid the epidemic levels of youth use of e-cigarettes and the popularity of certain products among children, the U.S. Food and Drug Administration today issued a policy prioritizing enforcement against certain unauthorized flavored e-cigarette products ...Leggi tutto
FDA to Review Eflapegrastim for Chemo-Induced Neutropenia
January 2, 2020 - The FDA has accepted a biologics license application (BLA) to review eflapegrastim for the management of chemotherapy-induced neutropenia, according to Spectrum Pharmaceuticals, the developer of the novel long-acting granulocyte-colony stimulating factor ...Leggi tutto
FDA Pooled Analysis of CDK4/6 Inhibitor Treatment for Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer
January 7, 2020 - In a U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Jennifer J. Gao, MD, and colleagues found that the magnitude of progression-free survival benefit with the addition of a cyclin-dependent kinase (CDK) 4/6 inhibitor ...Leggi tutto
NICE Cites Cost in Deciding Against Atezolizumab for Frontline Advanced Small Cell Lung Cancer
January 6, 2020 - The United Kingdom’s National Institute for Health and Care Excellence (NICE) did not recommend granting marketing authorization to atezolizumab in combination with carboplatin and etoposide for the treatment of patients with treatment-naïve ...Leggi tutto
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer
In the CLASSIC and MAGIC trials, microsatellite instability (MSI)-high status was a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant chemotherapy in resectable gastric cancer (GC). Given the low prevalence of MSI-high status in GC and ...Leggi tutto
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10). E1609 evaluated the safety and efficacy of ipilimumab at 3 mg/kg (ipi3) and ...Leggi tutto
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
Denosumab is a fully human monoclonal antibody that binds to, and inhibits, the receptor activator of RANKL (TNFSF11) and might affect breast cancer biology, as shown by preclinical evidence. We aimed to assess whether denosumab combined with standard-of-care adjuvant or ...Leggi tutto